Osteoclasts play a critical role in both normal bone metabolism and bone resorption in the joints of patients with rheumatoid arthritis. It has been reported that non-steroidal anti-inflammatory drugs (NSAIDs) inhibit murine osteoclastogenesis in vitro and murine arthritis models in vivo, but not the destruction of joints of patients with rheumatoid arthritis. In the current review article, we review the recent findings in the effect of NSAIDs on the formation and function of human and murine osteoclasts both in vitro and in vivo, underlining the importance of studies using human osteoclasts. Since 2009, we have suggested a novel term ‘human osteoclastology’.
References
[1]
Kong, Y.Y.; Feige, U.; Sarosi, I.; Bolon, B.; Tafuri, A.; Morony, S.; Capparelli, C.; Li, J.; Elliott, R.; McCabe, S.; Wong, T.; Campagnuolo, G.; Moran, E.; Bogoch, E.R.; Van, G.; Nguyen, L.T.; Ohashi, P.S.; Lacey, D.L.; Fish, E.; Boyle, W.J.; Penninger, J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature？1999, 402, 304–309, doi:10.1038/46303. 10580503
[2]
Horwood, N.J.; Kartsogiannis, V.; Quinn, J.M.; Romas, E.; Martin, T.J.; Gillespie, M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun.？1999, 265, 144–150, doi:10.1006/bbrc.1999.1623. 10548505
[3]
Kotake, S.; Udagawa, N.; Hakoda, M.; Mogi, M.; Yano, K.; Tsuda, E.; Takahashi, K.; Furuya, T.; Ishiyama, S.; Kim, K.J.; Saito, S.; Nishikawa, T.; Takahashi, N.; Togari, A.; Tomatsu, T.; Suda, T.; Kamatani, N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum.？2001, 44, 1003–1012, doi:10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#. 11352231
[4]
Kotake, S.; Udagawa, N.; Takahashi, N.; Matsuzaki, K.; Itoh, K.; Ishiyama, S.; Saito, S.; Inoue, K.; Kamatani, N.; Gillespie, M.T.; Martin, T.J.; Suda, T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest.？1999, 103, 1345–1352, doi:10.1172/JCI5703. 10225978
[5]
Kotake, S.; Nanke, Y.; Yago, T.; Kawamoto, M.; Yamanaka, H. Human osteoclastogenic T cells and human osteoclastology (Editorial). Arthritis. Rheum.？2009, 60, 3158–3163, doi:10.1002/art.24886. 19877050
Kotake., S.; Nanke, Y.; Mogi, M.; Kawamoto, M.; Furuya, T.; Yago, T.; Kobashigawa, T.; Togari, A.; Kamatani, N. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur. J. Immunol.？2005, 35, 3353–3363, doi:10.1002/eji.200526141. 16220542
[8]
Luxenburg, C.; Geblinger, D.; Klein, E.; Anderson, K.; Hanein, D.; Geiger, B.; Addadi, L. The architecture of the adhesive apparatus of cultured osteoclasts: From podosome formation to sealing zone assembly. PLoS ONE？2007, 2, e179, doi:10.1371/journal.pone.0000179. 17264882
[9]
Fuller, K.; Kirstein, B.; Chambers, T.J. Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin. Sci. (Lond).？2007, 112, 567–575, doi:10.1042/CS20060274. 17241109
[10]
Shimizu, S.; Shiozawa, S.; Shiozawa, K.; Imura, S.; Fujita, T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum.？1985, 28, 25–31, doi:10.1002/art.1780280105. 3966938
[11]
Kotake, S.; Sato, K.; Kim, K.J.; Takahashi, N.; Udagawa, N.; Nakamura, I.; Yamaguchi, A.; Kishimoto, T.; Suda, T.; Kashiwazaki, S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res.？1996, 11, 88–95. 8770701
[12]
Kotake, S.; Higaki, M.; Sato, K.; Himeno, S.; Morita, H.; Kim, K.J.; Nara, N.; Miyasaka, N.; Nishioka, K.; Kashiwazaki, S. Detection of myeloid precursors (granulocyte/macrophage colony forming units) in the bone marrow adjacent to rheumatoid arthritis joints. J. Rheumatol.？1992, 19, 1511–1516. 1464860
[13]
Kotake, S.; Schumacher, H.R., Jr.; Yarboro, C.H.; Arayssi, T.K.; Pando, J.A.; Kanik, K.S.; Gourley, M.F.; Klippel, J.H.; Wilder, R.L. In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc. Assoc. Am. Physicians？1997, 109, 286–301. 9154645
[14]
Kotake, S.; Schumacher, H.R., Jr.; Arayssi, T.K.; Gerard, H.C.; Branigan, P.J.; Hudson, A.P.; Yarboro, C.H.; Klippel, J.H.; Wilder, R.L. Gamma interferon and interleukin-10 gene expression in synovial tissues from patients with early stages of Chlamydia-associated arthritis and undifferentiated oligoarthritis and from healthy volunteers. Infect. Immun.？1999, 67, 2682–2686. 10225943
[15]
Kotake, S.; Schumacher, H.R., Jr.; Wilder, R.L. A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples. J. Immunol. Methods？1996, 199, 193–203, doi:10.1016/S0022-1759(96)00184-6. 8982362
[16]
Takahashi, N.; Akatsu, T.; Udagawa, N.; Sasaki, T.; Yamaguchi, A.; Moseley, J.M.; Martin, T.J.; Suda, T. Osteoblastic cells are involved in osteoclast formation. Endocrinology？1988, 123, 2600–2602, doi:10.1210/endo-123-5-2600. 2844518
[17]
Udagawa, N.; Takahashi, N.; Akatsu, T.; Tanaka, H.; Sasaki, T.; Nishihara, T.; Koga, T.; Martin, T.J.; Suda, T. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA？1990, 87, 7260–7264, doi:10.1073/pnas.87.18.7260. 2169622
[18]
Suda, T.; Udagawa, N.; Nakamura, I.; Miyaura, C.; Takahashi, N. Modulation of osteoclast differentiation by local factors. Bone？1995, 17 (2 Suppl.1), 87–91, doi:10.1016/8756-3282(95)00185-G. 8579904
[19]
Udagawa, N.; Kotake, S.; Kamatani, N.; Takahashi, N.; Suda, T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis. Res.？2002, 4, 281–289, doi:10.1186/ar431. 12223101
[20]
Lam, J.; Nelson, C.A.; Ross, F.P.; Teitelbaum, S.L.; Fremont, D.H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest.？2001, 108, 971–979, doi:10.1172/JCI13890. 11581298
[21]
Kotake, S.; Nanke, Y.; Kawamoto, M.; Yago, T.; Udagawa, N.; Ichikawa, N.; Kobashigawa, T.; Saito, S.; Momohara, S.; Kamatani, N.; Yamanaka, H. T-cell leukemia translocation-associated gene (TCTA) protein is required for human osteoclastogenesis. Bone？2009, 45, 627–639, doi:10.1016/j.bone.2009.06.019. 19560569
[22]
Baecher-Allan, C.; Brown, J.A.; Freeman, G.J.; Hafler, D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol.？2001, 167, 1245–1253, doi:10.4049/jimmunol.167.3.1245. 11466340
[23]
Nanke, Y.; Kotake, S.; Goto, M.; Ujihara, H.; Matsubara, M.; Kamatani, N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack: a possible predictive marker of ocular attack. Mod. Rheumatol.？2008, 18, 354–358, doi:10.3109/s10165-008-0064-x. 18427720
[24]
Testa, N.G.; Allen, T.D.; Lajtha, L.G.; Onions, D.; Jarret, O. Generation of osteoclasts in vitro. J. Cell. Sci.？1981, 47, 127–137. 7263774
[25]
Ibbotson, K.J.; Roodman, G.D.; McManus, L.M.; Mundy, G.R. Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells. J. Cell. Biol.？1984, 471–480.
[26]
Ibbotson, K.J.; Roodman, G.D.; McManus, L.M.; Mundy, G.R. Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells. J. Cell. Biol.？1984, 471–480.
[27]
Takahashi, N.; Yamana, H.; Yoshiki, S.; Roodman, G.D.; Mundy, G.R.; Jones, S.J.; Boyde, A.; Suda, T. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology？1988, 122, 1373–1382, doi:10.1210/endo-122-4-1373. 3345718
[28]
Hattersley, G.; Chambers, T.J. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology？1989, 125, 1606–1612, doi:10.1210/endo-125-3-1606. 2547591
[29]
Sato, K.; Fujii, Y.; Kasono, K.; Saji, M.; Tsushima, T.; Shizume, K. Stimulation of prostaglandin bone resorption by recombinant human interleukin 1 in fetal mouse bone. Biochem. Biophys. Res. Commun.？1986, 138, 618–624, doi:10.1016/S0006-291X(86)80541-1. 3488738
[30]
Liu, X.H.; Kirschenbaum, A.; Yao, S.; Levine, A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system. Endocrinology？2005, 146, 1991–1998, doi:10.1210/en.2004-1167. 15618359
[31]
Wani, M.R.; Fuller, K.; Kim, N.S.; Choi, Y.; Chambers, T. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology？1999, 140, 1927–1935, doi:10.1210/en.140.4.1927. 10098533
[32]
Kobayashi, Y.; Mizoguchi, T.; Take, I.; Kurihara, S.; Udagawa, N.; Takahashi, N. Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J. Biol. Chem.？2005, 280, 11395–11403, doi:10.1074/jbc.M411189200. 15647289
[33]
Han, S.Y.; Lee, N.K.; Kim, K.H.; Jang, I.W.; Yim, M.; Kim, J.H.; Lee, W.J.; Lee, S.Y. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood？2005, 106, 1240–1245, doi:10.1182/blood-2004-12-4975. 15860667
[34]
Ono, K.; Kaneko, H.; Choudhary, S.; Pilbeam, C.C.; Lorenzo, J.A.; Akatsu, T.; Kugai, N.; Raisz, L.G. Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J. Bone. Miner. Res.？2005, 20, 23–29, doi:10.1359/jbmr.2005.20.1.23. 15619666
[35]
Leonhardt, A.; Timmermanns, G.; Roth, B.; Seyberth, H.W. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J. Pediatr.？1992, 120, 546–554, doi:10.1016/S0022-3476(05)82480-1. 1340758
[36]
Neale, S.D.; Fujikawa, Y.; Sabokbar, A.; Gundle, R.; Murray, D.W.; Graves, S.E.; Howie, D.W.; Athanasou, N.A. Human bone-derived cells support formation of human osteoclasts from arthroplasty-derived cells in vitro. J. Bone. Joint. Surg. Br.？2000, 82, 892–900, doi:10.1302/0301-620X.82B6.10175. 10990320
[37]
Tsukii, K.; Shima, N.; Mochizuki, S.; Yamaguchi, K.; Kinosaki, M.; Yano, K.; Shibata, O.; Udagawa, N.; Yasuda, H.; Suda, T.; Higashio, K. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun.？1998, 246, 337–341, doi:10.1006/bbrc.1998.8610. 9610359
[38]
Nagai, M.; Sato, N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun.？1999, 257, 719–723, doi:10.1006/bbrc.1999.0524. 10208850
[39]
Lader, C.S.; Flanagan, A.M. Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology？1998, 139, 3157–3164, doi:10.1210/en.139.7.3157. 9645689
[40]
Itonaga, I.; Sabokbar, A.; Neale, S.D.; Athanasou, N.A. 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. Biochem. Biophys. Res. Commun.？1999, 264, 590–595, doi:10.1006/bbrc.1999.1545. 10529407
[41]
Kwan Tat, S.; Pelletier, J.P.; Lajeunesse, D.; Fahmi, H.; Duval, N.; Martel-Pelletier, J. Differential modulation of RANKL isoforms by human osteoarthriticsubchondral bone osteoblasts: Influence of osteotropic factors. Bone？2008, 43, 284–291, doi:10.1016/j.bone.2008.04.006. 18539107
[42]
Stamp, L.K.; James, M.J.; Cleland, L.G. Paracrineupregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: role of interleukin 17 and interferon-gamma. J. Rheumatol.？2004, 31, 1255–1264. 15229941
[43]
Stamp, L.K.; Cleland, L.G.; James, M.J. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J. Rheumatol.？2004, 31, 1246–1254. 15229940
[44]
Yago, T.; Nanke, Y.; Ichikawa, N.; Kobashigawa, T.; Mogi, M.; Kamatani, N.; Kotake, S. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: A novel mechanism of osteoclastogenesis by IL-17. J. Cell. Biochem.？2009, 108, 947–955, doi:10.1002/jcb.22326. 19728295
[45]
Lam, J.; Takeshita, S.; Barker, J.E.; Kanagawa, O.; Ross, F.P.; Teitelbaum, S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest.？2000, 106, 1481–1488, doi:10.1172/JCI11176. 11120755
[46]
Zou, W.; Hakim, I.; Tschoep, K.; Endres, S.; Bar-Shavit, Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J. Cell. Biochem.？2001, 83, 70–83, doi:10.1002/jcb.1202. 11500955
[47]
Miranda-Carus, M.E.; Benito-Miguel, M.; Balsa, A.; Cobo-Ibanez, T.; Perez de Ayala, C.; Pascual-Salcedo, D.; Martín-Mola, E. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis. Rheum.？2006, 54, 1151–1164, doi:10.1002/art.21731. 16575870
[48]
Raza, K.; Falciani, F.; Curnow, S.J.; Ross, E.J.; Lee, C.Y.; Akbar, A.N.; Lord, J.M.; Gordon, C.; Buckley, C.D.; Salmon, M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis. Res. Ther.？2005, 7, R784–R795, doi:10.1186/ar1733. 15987480
[49]
Kokkonen, H.; S？derstr？m, I.; Rockl？v, J.; Hallmans, G.; Lejon, K.; Rantap？？Dahlqvist, S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis. Rheum.？2010, 62, 383–391. 20112361
[50]
Genovese, M.; Van den Bosch, F.; Roberson, S.; Bojin, S.; Biagini, I.; Ryan, P.; Sloan-Lancaster, J. LY2439821, a Humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis. Rheum.？2010. [Epub ahead of print]. 20112361
[51]
Yago, T.; Nanke, Y.; Kawamoto, M.; Furuya, T.; Kobashigawa, T.; Kamatani, N.; Kotake, S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis. Res. Ther.？2007, 9, R96, doi:10.1186/ar2297. 17888176
[52]
Chambers, T.J.; Fuller, K.; Athanasou, N.A. The effect of prostaglandins I2, E1, E2 and dibutyryl cyclic AMP on the cytoplasmic spreading of rat osteoclasts. Br. J. Exp. Pathol.？1984, 65, 557–566. 6091728
[53]
Fuller, K.; Chambers, T.J. Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts. J. Bone. Mines. Res.？1989, 4, 209–215.
[54]
Sarrazin, P.; Hackett, J.A.; Fortier, I.; Gallant, M.A.; de Brum-Fernandes, A. Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts. J. Rheumatol.？2004, 31, 1598–1606. 15290741
[55]
Hackett, J.A.; Allard-Chamard, H.; Sarrazin, P.; de Fatima Lucena, M.; Gallant, M.A.; Fortier, I.; Nader, M.; Parent, J.L.; Bkaily, G.; de Brum-Fernandes, A.J. Prostaglandin production by human osteoclasts in culture. J. Rheumatol.？2006, 33, 1320–1328. 16758505
[56]
Yin, M.J.; Yamamoto, Y.; Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-beta. Nature？1998, 396, 77–80, doi:10.1038/23948. 9817203
[57]
Jimi, E.; Aoki, K.; Saito, H.; D'Acquisto, F.; May, M.J.; Nakamura, I.; Sudo, T.; Kojima, T.; Okamoto, F.; Fukushima, H.; Okabe, K.; Ohya, K.; Ghosh, S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med.？2004, 10, 617–624. 15156202
[58]
Karakawa, A.; Fukawa, Y.; Okazaki, M.; Takahashi, K.; Sano, T.; Amano, H.; Yamamoto, M.; Yamada, S. Diclofenac sodium inhibits NFkappaB transcription in osteoclasts. J. Dent. Res.？2009, 88, 1042–1047, doi:10.1177/0022034509346147. 19828894
[59]
Feng, R.; Anderson, G.; Xiao, G.; Elliott, G.; Leoni, L.; Mapara, M.Y.; Roodman, G.D.; Lentzsch, S. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood？2007, 109, 2130–2138. 17095620
[60]
Kawashima, M.; Fujikawa, Y.; Itonaga, I.; Takita, C.; Tsumura, H. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod. Rheumatol.？2009, 19, 192–198, doi:10.1007/s10165-008-0149-6. 19198759
[61]
Niki, Y.; Takaishi, H.; Takito, J.; Miyamoto, T.; Kosaki, N.; Matsumoto, H.; Toyama, Y.; Tada, N. Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction. J. Immunol.？2007, 179, 639–646, doi:10.4049/jimmunol.179.1.639. 17579086
[62]
Idris, A.I.; Del Soldato, P.; Ralston, S.H.; van't Hof, R.J. The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production. Bone？2004, 35, 636–643, doi:10.1016/j.bone.2004.03.036. 15336599
[63]
Idris, A.I.; Ralston, S.H.; van't Hof, R.J. The nitrosylatedflurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur. J. Pharmacol.？2009, 602, 215–222, doi:10.1016/j.ejphar.2008.11.023. 19046964
[64]
Kellinsalmi, M.; Parikka, V.; Risteli, J.; Hentunen, T.; Leskel？, H.V.; Lehtonen, S.; Selander, K.; V？？n？nen, K.; Lehenkari, P. Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favoursadipocyte formation in vitro. Eur. J. Pharmacol.？2007, 572, 102–110, doi:10.1016/j.ejphar.2007.06.030. 17632097
[65]
Goodman, S.B.; Ma, T.; Mitsunaga, L.; Miyanishi, K.; Genovese, M.C.; Smith, R.L. Temporal effects of a COX-2-selective NSAID on bone ingrowth. J. Biomed. Mater. Res. A.？2005, 72, 279–287. 15666361
[66]
Vuolteenaho, K.; Moilanen, T.; Moilanen, E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic. Clin. Pharmacol. Toxicol.？2008, 102, 10–14. 17973900
[67]
Nanke, Y.; Kotake, S.; Ninomiya, T.; Furuya, T.; Ozawa, H.; Kamatani, N. Geranylgeranylacetone inhibits formation and function of human osteoclasts and prevents bone loss in tail-suspended rats and ovariectomized rats. Calcif. Tissue. Int.？2005, 77, 376–385, doi:10.1007/s00223-005-0123-7. 16362462
[68]
Nanke, Y.; Kawamoto, M.; Yago, T.; Chiba, J.; Yamanaka, H.; Kotake, S. Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Mod. Rheumatol.？2009, 19, 379–383, doi:10.1007/s10165-009-0183-z. 19526306
